Effects of a contraceptive containing drospirenone and ethinylestradiol on blood pressure, metabolic profile and neurohumoral axis in hypertensive women at reproductive age  by Morais, Tercio Lemos de et al.
European Journal of Obstetrics & Gynecology and Reproductive Biology 182 (2014) 113–117Effects of a contraceptive containing drospirenone and
ethinylestradiol on blood pressure, metabolic proﬁle and
neurohumoral axis in hypertensive women at reproductive age
Tercio Lemos de Morais a, Cassiana Giribela b,c, Marcelo Gil Nisenbaumc, Grazia Guerra b,
Nilson Mello c, Edmundo Baracat c, Fernanda M. Consolim-Colombo a,b,*
aUniversidade Nove de Julho (UNINOVE), Sa˜o Paulo, Brazil
bHypertension Unit, Heart Institute (InCor), University of Sa˜o Paulo, Sa˜o Paulo, Brazil
cGynecology Department, University of Sa˜o Paulo, Sa˜o Paulo, Brazil
A R T I C L E I N F O
Article history:
Received 24 April 2014
Received in revised form 27 August 2014
Accepted 3 September 2014
Keywords:
Oral contraceptives
Hypertension
Cardiovascular risk
A B S T R A C T
The use of combined oral contraceptives is widespread among hypertensive women despite being
associated with increased cardiovascular risk. Contraceptives containing drospirenone, which has
antimineralocorticoid properties, may have a positive or neutral effect on neurohumoral activation and
metabolic homeostasis of hypertensive women at reproductive age.
Objectives: To evaluate the effect of combined oral contraceptive containing drospirenone + ethiny-
lestradiol on the systemic blood pressure, metabolic variables and neurohumoral axis in hypertensive
women in reproductive age.
Design: Prospective controlled trial with 56 hypertensive women allocated in two groups: 30
volunteers under oral combined contraceptive use and 26 volunteers using non-hormonal contraceptive
methods. Subjects were tested before the introduction of the contraceptive method and 6 months after
its use. For data acquisition, we used continuous non-invasive beat-to-beat blood pressure curve
recordings and, for the biochemical and hormonal analyses two blood samples were obtained. Student’s t
test was used to determine differences between groups and moments and p < 0.05 was considered
statistically signiﬁcant.
Results: Comparing antropometric and blood pressure measurements, cardiac sympatho-vagal
modulation, baroreceptor sensitivity, metabolic and neurohumoral axis variables between baseline
and after 6 months, no signiﬁcant difference was detected in each group or between groups. Except
serum triglyceride levels which increased in the group of women using EE + DRSP after 6 months of use.
Conclusion: A contraceptive containing 20 mcg of ethinyl estradiol and 3 mg of drospirenone causes no
signiﬁcant changes in clinical and autonomic parameters, metabolic variables and neurohumoral axis of
hypertensive women.
 2014 Elsevier Ireland Ltd. All rights reserved.
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0301-2115/ 2014 Elsevier Ireland Ltd. All rights reserved.issues associated with pregnancy and contraception [1]. Hyperten-
sion is a major source of maternal and fetal morbidity and some
methods of contraception may further increase the risk of
cardiovascular events [2].
Combined oral contraceptive (OC) is one of the most commonly
prescribed birth control methods, used by millions of women in
many countries [3]. OCs induce mild increase of arterial blood
pressure in the general population, but in about 5% of the female
users it is likely to get higher results. Adverse effects on blood
pressure increase with age, duration of the use of OCs and the
presence of other risk factors such as smoking, obesity and prior
diagnosis of hypertension. Moreover, OCs may impose additional
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aldosterone system (RAAS) and also by causing metabolic
disarrangements and pro-thrombotic effects [4–6].
Even considering that contraception guidelines point to an
indication against the use of OC by uncontrolled hypertensive
women or with other cardiovascular risk factors, epidemiological
studies have shown that a high rate of hypertensive women are in
regular use of OC [1,7]. Furthermore, hypertensive women may
develop adverse effects related to the interaction of antihyperten-
sive drugs and OCs.
The types and doses of estrogens have been associated with the
adverse effects related to OCs [5,8].
Recent meta-analysis has shown that even OCs with low
hormone levels (ethinylestradiol, estradiol (EE)), associated or not
with new progestogens may still lead to thromboembolic events
causing increased cardiovascular risk in women in general [9–12].
Drospirenone (DRSP) is the most similar synthetic progestin to
the natural progesterone, and is structurally similar to spirono-
lactone, acting as an antagonist of aldosterone receptors with
clinically recognized antimineralocorticoid activity [13–15]. DRSP
molecule in combination with EE, initially studied as hormone
replacement therapy in hypertensive postmenopausal women
[16,17], demonstrated a high capability to neutralize the estrogen-
induced RAAS activation [18,19]. Moreover, OCs containing
EE + DRSP did not increase blood pressure and had little impact
on metabolic proﬁle in both normotensive young women [20] and
postmenopausal hypertensive women [21–23]. There are few
informations in the literature regarding to the effects of OCs
containing EE + DRSP used as a contraceptive method in the
population of hypertensive women. Therefore, the aim of this
study was to prospectively evaluate the impact of OC containing
EE + DRSP coadministered with antihypertensive drugs on arterial
blood pressure, metabolic homeostasis and neurohumoral axis in
hypertensive women.
Materials and methods
This study enrolled 60 hypertensive female volunteers
recruited from the outpatient clinics of the Gynecology Depart-
ment and Hypertension Unit of the General Hospital, School of
Medicine, University of Sa˜o Paulo, Brazil. The Research Ethics
Committee of the University of Sa˜o Paulo reviewed and approved
the study. All patients were submitted to a clinical examination by
both a cardiologist and a gynecologist.
The inclusion criteria were women aged between 20 and
40 years old, with previous diagnosis of essential arterial
hypertension under antihypertensive medications, and regular
menstrual cycles without the use of hormonal contraceptives for at
least 6 months prior to the study. The exclusion criteria were
women with uncontrolled hypertension, detected target organ
damage, positive pregnancy tests, current smoking, previous
episode of thromboembolism, autoimmune disease, morbid
obesity, diabetes mellitus and women who were taking any
chronic medication, except antihypertensive drugs [5].
Sample size
The minimum size of the sample was determined from a
pilot sample and a previous publication [20]. Two hemody-
namic variables and four autonomic tone parameters were
used. Considering that a type I error of 0.05 and a power of
0.8 would be necessary to detect a difference between the two
groups of 20% on average, the minimum necessary sample size
per group for the study of each of these six variables was
30 patients.Experimental design
All selected women were eligible for both the contraceptive
methods, i.e., OCs or non-hormonal methods. However, after being
counseled regarding the advantages, disadvantages and side
effects of each contraceptive method, the volunteers were free
to choose the type of contraception they wanted to use. Therefore,
women who agreed to participate in the study were allocated into
two groups, users and nonusers: (1) EE + DRSP group: women
who chose to use an OC containing 20 mcg EE + 3 mg DRSP, with 24
days of active pills and a 4 day pill-free interval (n = 30), (2) non-
OC group: women who chose to use a non-hormonal method of
contraception (condoms or copper IUD) (n = 30).
All volunteers were evaluated during the same menstrual cycle
phase: follicular phase at baseline for both groups; follicular phase
in the follow-up period for the control group; high hormonal phase
in the contraceptive group. All examinations were performed
during the same time of the day, and were conducted in a
temperature-controlled room. All patients were instructed to
abstain from exercise, caffeine and alcohol for 12 h before testing.
Evaluation methods for body mass index and ofﬁce blood pressure.
Body mass index (BMI) was obtained by using measures of
weight and height of each subject (weight/height2) acquired
during the basal evaluation and at the end of the study (6 months).
Blood pressure measurement (BP) in the ofﬁce was obtained
using the auscultatory method with a calibrated mercury
sphygmomanometer following the recent guideline technique
recommendations. Hemodynamic parameters obtained during
rest in supine position, with the Finometer1 device (FMS, Finapres
Medical System, Anhem, The Netherlands) [24,25].
Heart rate variability and autonomic nervous system parameters
The blood pressure curves obtained with the Finometer1 device
were simultaneously recorded in another computer equipped with
biological signal acquisition and signal conversion software (AT/
MCA-CODAS; DATAC Instruments Inc., Akron, Ohio, USA). The
sampling frequency of the signals was 1000 Hz. The stored signals
were subsequently subjected to an analysis routine that provided
values for HR variability, blood pressure and spontaneous
baroreﬂex sensitivity. After these signals were pre-ampliﬁed
(General Purpose Ampliﬁer; Stemtech, Inc., 4-GPA), they were
converted from analog into digital and then stored for later
analysis. Each heart beat was identiﬁed by the use of a specialized
algorithm implemented in Matlab MT (MATLAB 6.0, Mathworks)
that automatically detects systolic and diastolic pressure waves.
Forms of acquisition and analysis of variability was performed as
previously published protocol [20,26].
Biochemical and hormonal variables
Two blood samples (initial phase and with 6 months of COC use)
were obtained for biochemical and hormonal measurements
according to the routine standard protocols.
Statistical analysis
The variables of interest in both groups were assessed at
baseline and after 6 months of use of the chosen contraceptive
method. An intergroup comparison was performed of the mean of
each clinical parameter variable at baseline using Student’s t test or
the Mann–Whitney test, depending on the characteristics of each
variable. The mean of each variable was analyzed as a function of
time and group using the scores from the tests of generalized
Table 1
Anthropometric and clinical variables in women using EE + DRSP and nonusers (non
OC) at baseline and after 6 months of follow-up.
Non OC (n = 26) EE + DRSP (n = 30)
Baseline 6 months p Baseline 6 months p
Weight (kg) 74.4  3.3 73.8  3.4 0.08 77.5  2.6 76.4  2.6 0.04*
AC (cm) 95.9  2.6 94.8  2.6 0.76 97.9  2.0 97.2  2.0 0.66
BMI (kg/m2) 29.0  1.1 28.7  1.2 0.20 30.3  0.9 29.8  0.9 0.04*
SBP (mmHg) 129.0  2.5 130.3  2.4 0.70 127.8  2.1 126.6  2.5 0.57
DBP (mmHg) 87.6  1.9 87.0  1.4 0.57 83.9  1.3 83.7  1.8 0.93
Mean values standard error.
AC = abdominal circumference; BMI = body mass index; SBP = systolic blood
pressure; DBP = diastolic blood pressure.
* p < 0.05 baseline vs 6 months.
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Whitney test and Wilcoxon rank sum test).
Results
A total of 60 hypertensive women was included, 30 in each
group. However, four women of the non-OC group did not remain
in the study, due to the following reasons: they neither attended
the visits, nor collected tests or experienced adverse effects with
intra uterine disposable (IUD) and chose to start OC. None of the
women in this trial became pregnant during the study period. In
addition, the patients included in the protocol were not performing
regular exercise, and maintained the same diet during the follow-
up.
Table 1 shows the clinical data and ofﬁce blood pressure of the
non-OC and EE + DRSP groups who completed the study. Both
groups were comparable in age, BMI and blood pressure. The
groups have class I obesity and blood pressure at a controlled level.
These results show that women using EE + DRSP after 6 months
have a small reduction in weight and BMI. The same event could
not be observed in the control group. There were no signiﬁcant
changes in the systolic and diastolic blood pressure after 6 months
in either group.
Prescription of antihypertensive drugs was guided by the
current guidelines and was maintained unchanged during all
protocol. There were no differences regarding number and classes
of drugs used by both the groups. Monotherapy was used by 30%
and 36% of patients of non-OC and EE + DRSP groups, respectively.
Diuretics were the most prescribed drug (approximately 70% of
patients in both groups) and were used as monotherapy (21% and
20% of patients in non-OC and EE + DRSP groups, respectively) or in
association with other classes of antihypertensive drugs. Angio-
tensin converting enzyme inhibitors and angiotensin II receptor
blockers were used as monotherapy or in association with other
classes, in 52% and 57% of patients of non-OC and EE + DRSP
groups, respectively. Calcium channel inhibitors were prescribed
for few patients, around 7% in both groups.
The autonomic variables at baseline and after 6 months
referring to the two groups of female users and non-users of OCTable 2
Assessment of autonomic hypertensive women using EE + DRSP and non-users (contro
Non OC n = 26 
Baseline 6 months 
VAR (RR) 2109.2  337.8 3023.6  715.4 
% LF 51.5  3.69 49.0  3.63 
% HF 48.5  3.69 51.0  3.63 
LF/HF 1.5  0.3 1.3  0.3 
Alfa index (mmhg/ms) 7.0  0.7 7.6  0.8 
Mean values standard error.
* p < 0.05 baseline vs 6 months.are presented in Table 2. The sympathetic–vagal modulation and
baroreﬂex sensitivity have shown no statistically signiﬁcant
differences when comparing the time (baseline vs after 6 months)
of hypertensive women using EE + DRSP with nonusers.
Table 3 shows that women who did not use OCs had no changes
in the components of RAAS or in the concentrations of electrolytes
in the metabolism of lipids and glucose. However, it was possible
to see a signiﬁcant increase in the levels of triglycerides in the
subjects using EE + DRSP. There was also a trend towards increased
aldosterone and A/R ratio after 6 months of using OC, but no
changes in electrolytes were observed.
Comments
The main ﬁndings of this study can be summarized as the
following: hypertensive women using EE + DRSP have shown a
mild, but statistically signiﬁcant reduction in weight and BMI,
associated with a neutral proﬁle in the activation of the RAAS, and
the maintenance of the sympathetic–vagal balance and baroreﬂex
sensitivity. No changes were found in the blood pressure measured
in the ofﬁce or analyzed in a beat-to-beat basis for a short period of
time. Nevertheless, a negative impact of the use of EE + DRSP could
be observeded in hypertensive individuals: there was an increase
in triglycerides, approximately 41% after 6 months of use,
compared to baseline. All variables remained similar in the non-
OC group during the 6-months of follow-up period.
Drospirenone is an analog of spironolactone, with biochemical
and pharmacological proﬁles that are similar to those of
endogenous progesterone, with an antimineralocorticoid property
and a mild anti-androgenic activity. It was initially developed in
combination with EE (17-b estradiol) for the treatment of hormone
replacement in hypertensive postmenopausal women [23]. It has
the capacity not only to neutralize the induced RAAS stimulation by
estrogen, but also to block testosterone receptors, decreasing the
androgenic effects [18,19]. The use of EE in low doses associated with
DRSP has been used as contraceptives for more than a decade. This
combination, compared to the previous generations of contra-
ceptives, has a better androgen proﬁle [5,8]; however, it keeps an
increased risk of pro-thrombogenic effects [9–12].
In a double-blind randomized study, it was evaluated the effect
of DRSP + EE in hypertensive postmenopausal women already
receiving enalapril [21]. An assessment of the plasma renin activity
and serum aldosterone was measured before the treatment and at
the end of treatment (day 14). The authors have demonstrated that
the plasma renin activity and aldosterone levels showed no
statistically signiﬁcant difference between the groups. However, a
small and non signiﬁcant increase in aldosterone levels in patients
that received DRSP + EE which was consistent with an antiminer-
alocorticoid effect due to DRSP, could be observed in previous
studies [18,21]. It is important to show that the OC used in this
study did not increase the serum aldosterone levels, as these,
independent of angiotensin II, have serious implications in the
pathogenesis of the progressive renal and cardiovascular diseasel) of COHCs: baseline and after 6 months of follow-up.
p EE + DRSP n = 30 p
Baseline 6 months
0.16 3031.8  595.3 2387.9  286.1 0.30
0.57 50.2  3.0 50.9  3.1 0.82
0.57 49.8  3.0 49.1  3.1 0.82
0.40 1.3  0.2 1.3  0.2 0.99
0.52 8.1  0.8 8.0  0.5 0.88
Table 3
Metabolic assessment of hypertensive women using EE + DRSP and nonusers (control) using COHC: baseline and after 6 months of follow-up.
Non OC (n = 26) p EE + DRSP (n = 30) p
Baseline 6 months Baseline 6 months
Renin (ng/mL/h) 4.8  1.3 4.0  1.1 0.70 4.9  0.8 4.6  0.9 0.87
Aldosterone (ng/dL) 12.3  1.6 11.0  1.7 0.82 9.8  1.0 13.9  1.7 0.13
Aldosterone/renin ratio 2.65  1.5 2.57  1.54 0.88 2.1  1.0 3.0  1.5 0.78
Potassium (mEq/L) 4.1  0.1 4.2  0.1 0.26 4.1  0.0 4.1  0.1 0.56
Sodium (mEq/L) 139.4  0.7 141.2  0.7 0.05 139.9  0.7 138.1  0.7 0.54
Creatinine (mg/dL) 0.8  0.0 0.7  0.0 0.41 0.8  0.0 0.7  0.0 0.33
Urea (mg/dL) 32.1  1.6 29.4  1.7 0.33 28.1  1.2 27.0  1.3 0.79
Glucose (mg/dL) 94.7  2.1 96.3  3.2 0.31 96.7  1.8 94.1  2.5 0.27
Insulin (UI) 14.4  3.2 12.3  1.4 0.55 13.7  2.2 13.3  2.1 0.86
HOMA1 (IR) a 3.2  0.5 3.0  0.4 0.59 3.1  0.5 2.9  0.4 0.59
Cholesterol (mg/dL) 188.1  7.9 186.3  6.9 0.74 197.6  8.6 195.9  10.9 0.73
LDL-col. (mg/dL) 109.8  7.9 110.5  6.7 0.88 118.1  9.3 102.7  11.6 0.27
HDL-col. (mg/dL) 58.2  2.7 55.6  2.5 0.46 54.6  2.0 60.2  2.3 0.06
Triglycerides (mg/dL) 100.2  9.1 100.6  10.5 0.98 124.3  12.1 174.7  14.7 0.01*
Hemoglobin (g/dL) 13.3  0.2 13.1  0.3 0.81 13.5  0.2 12.9  0.1 0.08
Platelet (mil/mm3) 268.6  16.5 268.9  15.8 0.67 286.2  15.3 296.4  13.2 0.42
Mean values standard error.
* p < 0.05 baseline vs 6 months.
a HOMA1 = < 2.8 normal cut-off value, according to Geloneze et al. [31].
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aldosterone receptors with spironolactone may signiﬁcantly
reduce the risk of morbidity and mortality in patients with severe
heart failure [27]. It has become of great interest to research on the
antagonism of aldosterone receptors in combination with the
antagonists of angiotensin receptors or ACE inhibitors [21,27,28].
In hypertensive women using anti-hypertensive drugs, which
per se can already alter potassium levels, the concomitant use of a
drug with spironolactone-like activity could lead to a stronger
electrolyte disturbance [22,28]. In a previous study with hyper-
tensive postmenopausal women using RAAS inhibitors it was
shown that only 7% of women had at least one value that was equal
to or greater than 5.5 mEq/L during the treatment with DRSP,
regarded as transient hyperkalemia; the values returned to
baseline levels at the end of the observation period [22,23]. Potas-
sium levels, commonly elevated in hypertensive women, did not
increase at the end of this study. This may be associated with the
use of diuretics by most hypertensive patients included in the trial,
separately, or associated with the RAAS inhibitors. The other
presecribed antihypertensives do not show, as a characteristic, an
increase in potassium. The importance of studying the serum
potassium levels is due to their relation with the development of
severe cardiac arrhythmias during hyperkalemia [28]. It was
emphasized that the presence of hyperkalemia would limit the use
of COHC with drospirenone [23]. It has been reported that DRSP
could change the concentration of plasmatic sodium [13];
however, this fact could not be observed in the patients in this
study, either.
We must take in account that the conclusions regarding the
effects of drosperinone on RAAS axis of hypertensive women were
obtained when drosperinone was administered on top of usual
antihypertensive drugs. Therefore, drosperinone in combination
with antihypertensive drugs, including diuretics or RAAS inhibi-
tors, is well tolerated by hypertensive women, without signiﬁcant
deleterious effects on RAAS axis.
Hypertension is characterized by changes in the autonomic
control, particularly in the sympathetic–vagal modulation to the
heart and baroreﬂex sensitivity, which can be improved with the
use of antihypertensive drugs and BP control [29]. DRSP could have
a positive impact on the autonomic parameters; however, no
inﬂuence of this drug on autonomic variables could be observed.
Hypertensive postmenopausal women using DRSP have shown
slight, but signiﬁcant reductions in BP detected by ambulatory BP
monitoring [21,23].Through the ways of BP measurement used in this study
(pressure measurement in the ofﬁce and in short time rest
records), it was not possible to show an impact in reducing BP. It is
likely that by using long-term monitoring, such an effect might be
shown. The demonstration that OC containing EE + DRSP used by
hypertensive women causes neither increased blood pressure nor
modiﬁcations in hemodynamic and autonomic parameters is
clinically relevant, since the autonomous system is considered one
of the most important mechanisms underlying the pathogenesis of
hypertension and cardiovascular disease [29,30]. Since the present
study lacks power to identify small but clinically relevant blood
pressure changes, more studies addressing this point are desired.
In conclusion, the use of the third-generation OC containing
EE + DRSP by young hypertensive women using anti-hypertensive
drugs has not been associated with neither neurohumoral
activation, nor electrolyte or metabolic abnormalities except for
an increase in triglycerides. Thus, DRSP seems to have a good safety
proﬁle regarding this female population, and its indication or not
depends on other adverse drug effects, particularly, the risk of
thromboembolic events.
Condensation
Drospirenone and ethinyl estradiol use for young hyperten-
sive women using anti-hypertensive drugs has not been
associated with neither neurohumoral activation, nor electrolyte
or metabolic.
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